CTOs on the Move

Onconano Medicine

www.onconanomed.com

 
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Onconano Medicine raised $11.7M on 05/17/2018
Onconano Medicine raised $22M on 04/24/2019
Onconano Medicine raised $23.7M on 09/04/2019
Onconano Medicine raised $15.4M on 08/27/2019

Similar Companies

Nanostics

Nanostics is a precision health company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. Their core technology is an advanced liquid biopsy platform that can accurately diagnose can...

The Canadian Cancer Research Group

The Canadian Cancer Research Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioLab Sciences

BioLab Sciences is a regenerative medicine company focused on creating new ways to heal the body. Headquartered in Scottsdale, Arizona, BioLab Sciences is uncovering better ways to address orthopedic injuries, wound care, pain management, aesthetic medicine, respiratory ailments, cardiovascular indications, ophthalmic issues, and more. BioLab Sciences is transforming wound care through MyOwn Skin™, a remarkable biotechnology that leverages a small sample of a patient`s own skin from a non-surgical procedure to produce up to three 4-inch x 4-inch skin grafts in a week.

Comp-U-charge

Comp-U-charge is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paragon Bioservices

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon`s aim is to build strong client partnerships with the world`s best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.